## Tomoya Sagawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8640131/publications.pdf

Version: 2024-02-01

		1684188	1372567	
10	99	5	10	
papers	citations	h-index	g-index	
10	10	10	161	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Exposure to particulate matter upregulates ACE2 and TMPRSS2 expression in the murine lung. Environmental Research, 2021, 195, 110722.	7.5	37
2	Upregulation of sphingosine-1-phosphate receptor 3 on fibroblast-like synoviocytes is associated with the development of collagen-induced arthritis via increased interleukin-6 production. PLoS ONE, 2019, 14, e0218090.	2.5	19
3	Use of protease inhibitors for the prevention of COVID-19. Preventive Medicine, 2020, 141, 106280.	3.4	11
4	Role of necroptosis of alveolar macrophages in acute lung inflammation of mice exposed to titanium dioxide nanoparticles. Nanotoxicology, 2021, 15, 1312-1330.	3.0	10
5	Association between preexisting lung involvements and the risk of diffuse alveolar hemorrhage in patients with microscopic polyangiitis: A multi-center retrospective cohort study. Modern Rheumatology, 2020, 30, 338-344.	1.8	8
6	CG223, a novel BET inhibitor, exerts TGF- $\hat{l}^2$ 1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2021, 70, 102057.	2.6	6
7	Utility of Coagulation Markers for the Prediction of Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis. Lung, 2019, 197, 437-442.	3.3	3
8	Role of IL-6 in Severe Inflammation. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 140-141.	5.6	2
9	COVID-19 and Coagulopathy. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 764-764.	2.9	2
10	Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors. Critical Care, 2020, 24, 511.	5.8	1